SUPPLEMENT

Q3 2026 — Financial disclosures

Q3 2026PDF · 10 pages1.1 MB
Merck & Co., Inc.,
Rahway, N.J., USA
Financial Highlights Package
Third Quarter 2026
Table of Contents
Table 1: GAAP P&L....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2
Table 2a: GAAP to Non-GAAP Reconciliation 3Q26 and Sep YTD 26........3
Table 2b: GAAP to Non-GAAP Reconciliation 3Q25 and Sep YTD 25........4
Table 3: Sales - Current Year and Prior Year by Quarter...........................5
Table 3a: Sales – U.S. / International 3Q26.................................................6
Table 3b: Sales – U.S. / International Sep YTD 26......................................7
Table 3c: Sales – Pharmaceutical Geographic Split....................................8
Table 4: Other (Income) Expense .............................................................9

-- 1 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP %
Change
GAAP %
Change
3Q26 3Q25 Sep YTD
2026 Sep YTD
2025
Sales $18,085 $17,276 5% $50,978 $48,611 5%
Costs, Expenses and Other
Cost of sales 4,892 3,855 27% 13,482 10,831 24%
Selling, general and administrative 2,886 2,633 10% 8,491 7,835 8%
Research and development 4,537 4,234 7% 26,871 11,903 *
Restructuring costs 184 47 * 530 676 -22%
Other (income) expense, net 27 (238) * 262 (281) *
Income Before Taxes 5,559 6,745 -18% 1,342 17,647 -92%
Income Tax Provision 492 958 1,855 2,346
Net Income (Loss) 5,067 5,787 -12% (513) 15,301 *
Less: Net Income (Loss) Attributable to Noncontrolling Interests 2 2 (3) 10
Net Income (Loss) Attributable to Merck & Co., Inc., Rahway, N.J., USA $ 5,065 $ 5,785 -12% $ (510) $15,291 *
Earnings (Loss) per Common Share Assuming Dilution (1) $ 2.04 $ 2.32 -12% $ (0.21) $ 6.08 *
Average Shares Outstanding Assuming Dilution (1) 2,478 2,498 2,471 2,514
Effective Income Tax Rate 8.9% 14.2% 138.2% 13.3%
* 100% or greater
(1) Because the Company recorded a net loss in the first nine months of 2026, no potential dilutive common shares were used in the computation of loss per common share
assuming dilution as the effect would have been anti-dilutive.
1

-- 2 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1a
2026 2025 % Change
1Q 2Q 3Q Sep
YTD 1Q 2Q 3Q Sep
YTD 4Q Full
Year 3Q Sep
YTD
Sales $ 16,286 $ 16,607 $ 18,085 $ 50,978 $ 15,529 $ 15,806 $ 17,276 $ 48,611 $ 16,400 $ 65,011 5% 5%
Costs, Expenses and Other
Cost of sales 4,195 4,395 4,892 13,482 3,419 3,557 3,855 10,831 5,551 16,382 27% 24%
Selling, general and administrative 2,700 2,904 2,886 8,491 2,552 2,649 2,633 7,835 2,898 10,733 10% 8%
Research and development 12,592 9,741 4,537 26,871 3,621 4,048 4,234 11,903 3,886 15,789 7% *
Restructuring costs 195 151 184 530 69 560 47 676 213 889 * -22%
Other (income) expense, net 138 99 27 262 (35) (7) (238) (281) 432 151 * *
(Loss) Income Before Taxes (3,534) (683) 5,559 1,342 5,903 4,999 6,745 17,647 3,420 21,067 -18% -92%
Income Tax Provision 709 654 492 1,855 818 571 958 2,346 458 2,804
Net (Loss) Income (4,243) (1,337) 5,067 (513) 5,085 4,428 5,787 15,301 2,962 18,263 -12% *
Less: Net (Loss) Income Attributable to
Noncontrolling Interests (3) (2) 2 (3) 6 1 2 10 (1) 9
Net (Loss) Income Attributable to Merck & Co., Inc.,
Rahway, N.J., USA $ (4,240) $ (1,335) $ 5,065 $ (510) $ 5,079 $ 4,427 $ 5,785 $ 15,291 $ 2,963 $ 18,254 -12% *
(Loss) Earnings per Common Share Assuming
Dilution (1) $ (1.72) $ (0.54) $ 2.04 $ (0.21) $ 2.01 $ 1.76 $ 2.32 $ 6.08 $ 1.19 $ 7.28 -12% *
Average Shares Outstanding Assuming Dilution (1)
2,472 2,470 2,478 2,471 2,531 2,513 2,498 2,514 2,488 2,507
Effective Income Tax Rate -20.1 % -95.9 % 8.9 % 138.2 % 13.9 % 11.4 % 14.2 % 13.3 % 13.4 % 13.3 %
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Because the Company recorded a net loss in the first and second quarters of 2026, as well as the first nine months of 2026, no potential dilutive common shares were
used in the computations of loss per common share assuming dilution as the effects would have been anti-dilutive.
2

-- 3 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
GAAP
Acquisition-
and
Divestiture-
Related
Costs (1)
Restructuring
Costs (2)
(Income)
Loss from
Investments
in Equity
Securities Adjustment
Subtotal Non-GAAP
Third Quarter
Cost of sales $ 4,892 1,140 396 1,536 $ 3,356
Selling, general and administrative 2,886 24 24 2,862
Research and development 4,537 3 1 4 4,533
Restructuring costs 184 184 184 —
Other (income) expense, net 27 (393) (393) 420
Income Before Taxes 5,559 (1,167) (581) 393 (1,355) 6,914
Income Tax Provision (Benefit) 492 (239) (3) (105) (3) 83 (3) (261) 753
Net Income 5,067 (928) (476) 310 (1,094) 6,161
Net Income Attributable to Merck &
Co., Inc., Rahway, N.J., USA 5,065 (928) (476) 310 (1,094) 6,159
Earnings per Common Share
Assuming Dilution $ 2.04 (0.38) (0.19) 0.12 (0.45) $ 2.49
Effective Income Tax Rate 8.9% 10.9%
September YTD
Cost of sales $ 13,482 3,221 817 4,038 $ 9,444
Selling, general and administrative 8,491 73 73 8,418
Research and development 26,871 9 34 43 26,828
Restructuring costs 530 530 530 —
Other (income) expense, net 262 (764) (764) 1,026
Income Before Taxes 1,342 (3,303) (1,381) 764 (3,920) 5,262
Income Tax Provision (Benefit) 1,855 (660) (3) (240) (3) 163 (3) (737) 2,592
Net (Loss) Income (513) (2,643) (1,141) 601 (3,183) 2,670
Net (Loss) Income Attributable to
Merck & Co., Inc., Rahway, N.J., USA (510) (2,643) (1,141) 601 (3,183) 2,673
(Loss) Earnings per Common Share
Assuming Dilution (4) $ (0.21) (1.07) (0.46) 0.24 (1.29) $ 1.08
Effective Income Tax Rate 138.2% 49.3%
Only the line items that are affected by non-GAAP adjustments are shown.
The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on
the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’
understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP
measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition,
annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-
GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with
GAAP.
(1) Amounts included in cost of sales reflect expenses for the amortization of intangible assets, as well as the recognition of fair value step-up of
inventories related to the 2025 Verona Pharma plc acquisition. Amounts included in selling, general and administrative expenses reflect integration,
transaction and certain other costs related to acquisitions and divestitures.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairment charges associated with facilities to be closed
or divested, as well as contractual termination costs, related to activities under the Company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP
adjustments.
(4) Because the Company recorded a net loss in the first nine months of 2026, no potential dilutive common shares were used in the computation of
loss per common share assuming dilution as the effect would have been anti-dilutive.
3

-- 4 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
GAAP
Acquisition-
and
Divestiture-
Related
Costs (1)
Restructuring
Costs (2)
(Income)
Loss from
Investments
in Equity
Securities Certain
Other Items Adjustment
Subtotal Non-GAAP
Third Quarter
Cost of sales $ 3,855 621 110 731 $ 3,124
Selling, general and administrative 2,633 34 34 2,599
Research and development 4,234 4 233 237 3,997
Restructuring costs 47 47 47 —
Other (income) expense, net (238) (344) (344) 106
Income Before Taxes 6,745 (659) (390) 344 (705) 7,450
Income Tax Provision (Benefit) 958 (119) (3) (82) (3) 73 (3) 86 (4) (42) 1,000
Net Income 5,787 (540) (308) 271 (86) (663) 6,450
Net Income Attributable to Merck & Co., Inc.,
Rahway, N.J., USA 5,785 (540) (308) 271 (86) (663) 6,448
Earnings per Common Share Assuming
Dilution $ 2.32 (0.22) (0.12) 0.11 (0.03) (0.26) $ 2.58
Effective Income Tax Rate 14.2% 13.4%
September YTD
Cost of sales $ 10,831 1,817 311 2,128 $ 8,703
Selling, general and administrative 7,835 72 1 73 7,762
Research and development 11,903 14 286 300 11,603
Restructuring costs 676 676 676 —
Other (income) expense, net (281) (3) (512) (515) 234
Income Before Taxes 17,647 (1,900) (1,274) 512 (2,662) 20,309
Income Tax Provision (Benefit) 2,346 (338) (3) (239) (3) 109 (3) (60) (4) (528) 2,874
Net Income 15,301 (1,562) (1,035) 403 60 (2,134) 17,435
Net Income Attributable to Merck & Co., Inc.,
Rahway, N.J., USA 15,291 (1,562) (1,035) 403 60 (2,134) 17,425
Earnings per Common Share Assuming
Dilution $ 6.08 (0.62) (0.41) 0.16 0.02 (0.85) $ 6.93
Effective Income Tax Rate 13.3% 14.2%
Only the line items that are affected by non-GAAP adjustments are shown.
The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of
underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because
management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the
performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a
non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in
accordance with GAAP.
(1) Amounts included in cost of sales for the third quarter reflect expenses for the amortization of intangible assets. Amounts included in cost of sales for the nine-month period
include the amortization of intangible assets and intangible asset impairment charges, partially offset by a decrease in the estimated fair value measurement of liabilities for
contingent consideration. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and
divestitures. Amounts included in research and development expenses reflect the amortization of intangible assets.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairment charges associated with facilities to be closed or divested, as well as
contractual termination costs, related to activities under the Company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Amount in the third quarter represents tax expense relating to audit reserve adjustments. Amount in the nine-month period represents a tax benefit, including a net benefit
related to favorable audit reserve adjustments.
4

-- 5 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2026 2025 3Q Sep YTD
1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep
YTD 4Q Full
Year Nom %
Ex-
Exch
% Nom %
Ex-
Exch
%
TOTAL SALES (1) $16,286 $16,607 $18,085 $50,978 $15,529 $15,806 $17,276 $48,611 $16,400 $65,011 5 4 5 4
PHARMACEUTICAL 14,349 14,760 16,268 45,377 13,638 14,050 15,611 43,299 14,843 58,142 4 4 5 4
Oncology
Keytruda 7,906 7,904 7,771 23,581 7,205 7,956 8,142 23,303 8,337 31,641 -5 -4 1 0
Keytruda Qlex 128 463 830 1,420 5 5 35 40 * * * *
Alliance Revenue – Lynparza (2) 341 365 352 1,059 312 370 379 1,061 389 1,450 -7 -7 0 -2
Alliance Revenue – Lenvima (2) 256 283 287 826 258 265 258 781 272 1,053 11 11 6 5
Welireg 199 271 307 776 137 162 196 496 220 716 56 58 57 57
Alliance Revenue – Reblozyl (3) 148 122 177 448 119 107 136 361 164 525 31 31 24 24
Vaccines & Infectious Diseases
Gardasil/Gardasil 9 1,069 1,169 1,995 4,232 1,327 1,126 1,749 4,202 1,031 5,233 14 14 1 0
ProQuad/M-M-R II/Varivax 538 592 730 1,860 539 609 684 1,832 619 2,451 7 7 2 1
Bridion 472 497 144 1,113 441 461 439 1,341 499 1,841 -67 -67 -17 -17
Prevymis 272 295 347 915 208 228 266 702 275 978 30 31 30 29
Capvaxive 142 184 263 588 107 129 244 480 279 759 8 7 22 22
Vaxneuvance 202 148 195 545 230 229 226 685 140 825 -14 -13 -20 -22
RotaTeq 206 134 196 536 228 121 204 554 119 673 -4 -4 -3 -4
Zerbaxa 82 77 90 249 70 74 81 225 87 312 11 11 11 9
Delstrigo 75 101 67 243 67 83 77 228 79 306 -13 -12 7 3
Enflonsia 1 2 187 190 79 79 21 100 138 136 142 140
Isentress/Isentress HD 59 60 52 171 90 86 82 258 67 325 -36 -36 -34 -34
Dificid 34 22 14 70 83 96 43 222 25 247 -68 -68 -68 -68
Lagevrio 28 5 17 49 102 83 138 323 57 380 -88 -88 -85 -85
Cardiometabolic, Respiratory, & Specialty
Winrevair 525 588 694 1,808 280 336 360 976 467 1,443 93 94 85 85
Januvia 367 258 186 811 549 372 382 1,302 302 1,604 -51 -50 -38 -37
Janumet 207 171 194 572 247 251 243 741 199 940 -20 -20 -23 -24
Ohtuvayre 131 204 184 519 178 178 — — — —
Alliance Revenue - Adempas/Verquvo (4) 109 126 118 353 106 123 112 340 129 470 5 5 4 4
Adempas (5) 78 78 78 234 68 80 82 229 83 312 -5 -3 2 -1
Other Pharmaceutical (6) 774 641 793 2,209 865 703 1,004 2,573 770 3,340 -21 -21 -14 -15
ANIMAL HEALTH 1,791 1,775 1,676 5,243 1,588 1,646 1,615 4,849 1,505 6,354 4 3 8 5
Livestock 1,064 1,041 1,048 3,154 924 961 1,023 2,909 987 3,896 2 2 8 5
Companion Animal 727 734 628 2,089 664 685 592 1,940 518 2,458 6 6 8 5
Other Revenues (7) 146 72 141 358 303 110 50 463 52 515 185 -25 -23 -8
*200% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in the Company's marketing territories.
(6) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $161 million, $10 million and $13 million in the first, second and third quarter of 2026,
respectively, and $44 million, $43 million and $214 million in the first, second and third quarter of 2025, respectively.
(7) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to
the receipt of milestone payments for out-licensed products were $132 million, $0 million and $2 million in the first, second and third quarter of 2026, respectively, and $95 million, $5 million and $11 million
in the first, second and third quarter of 2025, respectively.
5

-- 6 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
THIRD QUARTER 2026
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global U.S. International
3Q 2026 3Q 2025 %
Change 3Q 2026 3Q 2025 %
Change 3Q 2026 3Q 2025 %
Change
TOTAL SALES (1) $18,085 $17,276 5 $10,615 $10,012 6 $7,471 $7,264 3
PHARMACEUTICAL 16,268 15,611 4 10,119 9,493 7 6,149 6,118 1
Oncology
Keytruda 7,771 8,142 -5 4,520 4,879 -7 3,251 3,263 0
Keytruda Qlex 830 5 * 693 5 * 136 —
Alliance Revenue – Lynparza (2) 352 379 -7 171 184 -7 182 195 -7
Welireg 307 196 56 237 161 47 69 35 96
Alliance Revenue – Lenvima (2) 287 258 11 204 177 15 83 81 3
Alliance Revenue – Reblozyl (3) 177 136 31 145 111 31 33 25 31
Vaccines & Infectious Diseases
Gardasil/Gardasil 9 1,995 1,749 14 1,366 1,154 18 629 595 6
ProQuad/M-M-R II/Varivax 730 684 7 561 554 1 169 130 30
Prevymis 347 266 30 189 128 48 158 138 14
Capvaxive 263 244 8 207 238 -13 55 7 *
RotaTeq 196 204 -4 150 141 6 46 63 -28
Vaxneuvance 195 226 -14 111 134 -18 85 91 -7
Enflonsia 187 79 138 141 78 80 45 —
Bridion 144 439 -67 108 392 -72 36 47 -24
Zerbaxa 90 81 11 56 49 15 34 32 6
Delstrigo 67 77 -13 13 13 -3 54 64 -15
Isentress/Isentress HD 52 82 -36 31 44 -31 21 37 -43
Lagevrio 17 138 -88 7 24 -71 10 114 -91
Dificid 14 43 -68 7 30 -78 7 13 -44
Cardiometabolic, Respiratory, & Specialty
Winrevair 694 360 93 610 335 82 84 25 *
Janumet 194 243 -20 61 78 -22 133 165 -19
Januvia 186 382 -51 78 258 -70 108 124 -12
Ohtuvayre 184 — 184 —
Alliance Revenue - Adempas/Verquvo (4) 118 112 5 108 103 4 10 8 20
Adempas (5) 78 82 -5 78 82 -5
Other Pharmaceutical (6) 793 1,004 -21 161 223 -28 633 784 -19
ANIMAL HEALTH 1,676 1,615 4 493 504 -2 1,184 1,112 6
Livestock 1,048 1,023 2 199 213 -7 850 811 5
Companion Animal 628 592 6 294 291 1 334 301 11
Other Revenues (7) 141 50 185 3 15 -80 138 34 *
*200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in the Company's marketing territories.
(6) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $13 million and $214 million on a global basis in the third quarter of 2026
and 2025, respectively.
(7) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other
Revenues related to the receipt of milestone payments for out-licensed products were $2 million and $11 million on a global basis in the third quarter of 2026 and 2025, respectively.
6

-- 7 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
SEPTEMBER YEAR-TO-DATE 2026
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global U.S. International
Sep YTD
2026 Sep YTD
2025 %
Change Sep YTD
2026 Sep YTD
2025 %
Change Sep YTD
2026 Sep YTD
2025 %
Change
TOTAL SALES (1) $50,978 $48,611 5 $29,146 $27,371 6 $21,832 $21,240 3
PHARMACEUTICAL 45,377 43,299 5 27,457 25,747 7 17,920 17,552 2
Oncology
Keytruda 23,581 23,303 1 13,731 13,936 -1 9,851 9,367 5
Keytruda Qlex 1,420 5 * 1,195 5 * 225 —
Alliance Revenue – Lynparza (2) 1,059 1,061 0 486 503 -3 573 558 3
Alliance Revenue – Lenvima (2) 826 781 6 573 545 5 253 236 7
Welireg 776 496 57 603 422 43 173 74 133
Alliance Revenue – Reblozyl (3) 448 361 24 370 299 24 78 62 25
Vaccines & Infectious Diseases
Gardasil/Gardasil 9 4,232 4,202 1 2,392 2,235 7 1,840 1,967 -6
ProQuad/M-M-R II/Varivax 1,860 1,832 2 1,409 1,457 -3 452 374 21
Bridion 1,113 1,341 -17 995 1,181 -16 118 161 -26
Prevymis 915 702 30 472 345 37 443 357 24
Capvaxive 588 480 22 464 473 -2 124 8 *
Vaxneuvance 545 685 -20 303 409 -26 243 276 -12
RotaTeq 536 554 -3 399 366 9 137 187 -27
Zerbaxa 249 225 11 151 136 11 98 89 10
Delstrigo 243 228 7 36 42 -15 208 185 12
Enflonsia 190 79 142 140 78 79 50 —
Isentress/Isentress HD 171 258 -34 101 144 -29 70 114 -39
Dificid 70 222 -68 42 185 -78 29 37 -22
Lagevrio 49 323 -85 25 90 -73 25 233 -89
Cardiometabolic, Respiratory, & Specialty
Winrevair 1,808 976 85 1,609 926 74 198 49 *
Januvia 811 1,302 -38 479 819 -42 333 483 -31
Janumet 572 741 -23 156 210 -26 416 530 -22
Ohtuvayre 519 — 518 —
Alliance Revenue - Adempas/Verquvo (4) 353 340 4 329 308 7 24 32 -24
Adempas (5) 234 229 2 234 229 2
Other Pharmaceutical (6) 2,209 2,573 -14 479 633 -24 1,725 1,944 -11
ANIMAL HEALTH 5,243 4,849 8 1,547 1,505 3 3,696 3,345 10
Livestock 3,154 2,909 8 613 598 3 2,541 2,312 10
Companion Animal 2,089 1,940 8 934 907 3 1,155 1,033 12
Other Revenues (7) 358 463 -23 142 119 19 216 343 -37
*200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in the Company's marketing territories.
(6) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $183 million and $301 million on a global basis for September YTD 2026 and 2025,
respectively.
(7) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to
the receipt of milestone payments for out-licensed products were $133 million and $111 million on a global basis for September YTD 2026 and 2025, respectively.
7

-- 8 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
2026 2025 % Change
1Q 2Q 3Q Sep
YTD 1Q 2Q 3Q Sep
YTD 4Q Full
Year 3Q Sep
YTD
TOTAL PHARMACEUTICAL $14,349 $14,760 $16,268 $45,377 $13,638 $14,050 $15,611 $43,299 $14,843 $58,142 4 5
United States 8,512 8,827 10,119 27,457 7,927 8,328 9,493 25,747 8,662 34,409 7 7
% Pharmaceutical Sales 59.3 % 59.8 % 62.2 % 60.5 % 58.1 % 59.3 % 60.8 % 59.5 % 58.4 % 59.2 %
Europe (1) 2,725 2,801 2,837 8,363 2,384 2,551 2,675 7,610 2,839 10,449 6 10
% Pharmaceutical Sales 19.0 % 19.0 % 17.4 % 18.4 % 17.5 % 18.2 % 17.1 % 17.6 % 19.1 % 18.0 %
Latin America 624 636 730 1,990 589 654 691 1,933 644 2,578 6 3
% Pharmaceutical Sales 4.3 % 4.3 % 4.5 % 4.4 % 4.3 % 4.7 % 4.4 % 4.5 % 4.3 % 4.4 %
Asia Pacific (other than China and Japan) 569 636 596 1,800 535 609 593 1,736 586 2,323 1 4
% Pharmaceutical Sales 4.0 % 4.3 % 3.7 % 4.0 % 3.9 % 4.3 % 3.8 % 4.0 % 4.0 % 4.0 %
Japan 535 558 569 1,662 651 604 693 1,948 684 2,632 -18 -15
% Pharmaceutical Sales 3.7 % 3.8 % 3.5 % 3.7 % 4.8 % 4.3 % 4.4 % 4.5 % 4.6 % 4.5 %
Eastern Europe/Middle East/Africa 413 408 399 1,220 435 451 365 1,250 348 1,598 10 -2
% Pharmaceutical Sales 2.9 % 2.8 % 2.5 % 2.7 % 3.2 % 3.2 % 2.3 % 2.9 % 2.3 % 2.7 %
China 353 368 429 1,151 668 407 377 1,452 364 1,816 14 -21
% Pharmaceutical Sales 2.5 % 2.5 % 2.6 % 2.5 % 4.9 % 2.9 % 2.4 % 3.4 % 2.5 % 3.1 %
Canada 137 154 152 443 125 135 134 394 153 547 13 12
% Pharmaceutical Sales 1.0 % 1.0 % 0.9 % 1.0 % 0.9 % 1.0 % 0.9 % 0.9 % 1.0 % 0.9 %
Other 481 372 437 1,291 324 311 590 1,229 563 1,790 -26 5
% Pharmaceutical Sales 3.3 % 2.5 % 2.7 % 2.8 % 2.4 % 2.1 % 3.9 % 2.7 % 3.8 % 3.2 %
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
8

-- 9 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
3Q26 3Q25 Sep YTD
2026 Sep YTD
2025
Interest income $ (52) $ (96) $ (122) $ (274)
Interest expense 546 327 1,550 946
Exchange losses 63 56 138 224
Income from investments in equity securities, net (1) (401) (373) (811) (563)
Net periodic defined benefit plan (credit) cost other than service cost (120) (152) (382) (452)
Other, net (9) — (111) (162)
Total $ 27 $ (238) $ 262 $ (281)
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in
investment funds are accounted for on a one quarter lag.
9

-- 10 of 10 --